Charged Particles in Oncology

High-energy charged particles represent a cutting-edge technique in radiation oncology. Protons and carbon ions are used in several centers all over the world for the treatment of different solid tumors. Typical indications are ocular malignancies, tumors of the base of the skull, hepatocellular car...

Full description

Saved in:
Bibliographic Details
Superior document:Frontiers Research Topics
:
Year of Publication:2018
Language:English
Series:Frontiers Research Topics
Physical Description:1 electronic resource (650 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993544277104498
ctrlnum (CKB)4920000000094235
(oapen)https://directory.doabooks.org/handle/20.500.12854/43025
(EXLCZ)994920000000094235
collection bib_alma
record_format marc
spelling Marco Durante auth
Charged Particles in Oncology
Frontiers Media SA 2018
1 electronic resource (650 p.)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
Frontiers Research Topics
High-energy charged particles represent a cutting-edge technique in radiation oncology. Protons and carbon ions are used in several centers all over the world for the treatment of different solid tumors. Typical indications are ocular malignancies, tumors of the base of the skull, hepatocellular carcinomas and various sarcomas. The physical characteristics of the charged particles (Bragg peak) allow sparing of much more normal tissues than it is possible using conventional X-rays, and for this reason all pediatric tumors are considered eligible for protontherapy. Ions heavier than protons also display special radiobiological characteristics, which make them effective against radioresistant and hypoxic tumors. On the other hand, protons and ions with high charge (Z) and energy (HZE particles) represent a major risk for human space exploration. The main late effect of radiation exposure is cancer induction, and at the moment the dose limits for astronauts are based on cancer mortality risk. The Mars Science Laboratory (MSL) measured the dose on the route to Mars and on the planet’s surface, suggesting that a human exploration missions will exceed the radiation risk limits. Notwithstanding many studies on carcinogenesis induced by protons and heavy ions, the risk uncertainty remains very high. In this research topic we aim at gathering the experiences and opinions of scientists dealing with high-energy charged particles either for cancer treatment or for space radiation protection. Clinical results with protons and heavy ions, as well as research in medical physics and pre-clinical radiobiology are reported. In addition, ground-based and spaceflight studies on the effects of space radiation are included in this book. Particularly relevant for space studies are the clinical results on normal tissue complications and second cancers. The eBook nicely demonstrates that particle therapy in oncology and protection of astronauts from space radiation share many common topics, and can learn from each other.
English
carbon ions
heavy ions
Mars
proton therapy
radiotherapy
particle radiobiology
protons
space radiation protection
Charged particles
space travel
2-88945-391-X
Francis A. Cucinotta auth
Jay S. Loeffler auth
language English
format eBook
author Marco Durante
spellingShingle Marco Durante
Charged Particles in Oncology
Frontiers Research Topics
author_facet Marco Durante
Francis A. Cucinotta
Jay S. Loeffler
author_variant m d md
author2 Francis A. Cucinotta
Jay S. Loeffler
author2_variant f a c fac
j s l jsl
author_sort Marco Durante
title Charged Particles in Oncology
title_full Charged Particles in Oncology
title_fullStr Charged Particles in Oncology
title_full_unstemmed Charged Particles in Oncology
title_auth Charged Particles in Oncology
title_new Charged Particles in Oncology
title_sort charged particles in oncology
series Frontiers Research Topics
series2 Frontiers Research Topics
publisher Frontiers Media SA
publishDate 2018
physical 1 electronic resource (650 p.)
isbn 2-88945-391-X
illustrated Not Illustrated
work_keys_str_mv AT marcodurante chargedparticlesinoncology
AT francisacucinotta chargedparticlesinoncology
AT jaysloeffler chargedparticlesinoncology
status_str n
ids_txt_mv (CKB)4920000000094235
(oapen)https://directory.doabooks.org/handle/20.500.12854/43025
(EXLCZ)994920000000094235
carrierType_str_mv cr
hierarchy_parent_title Frontiers Research Topics
is_hierarchy_title Charged Particles in Oncology
container_title Frontiers Research Topics
author2_original_writing_str_mv noLinkedField
noLinkedField
_version_ 1796649071487746048
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03185nam-a2200409z--4500</leader><controlfield tag="001">993544277104498</controlfield><controlfield tag="005">20231214133540.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2018 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4920000000094235</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/43025</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994920000000094235</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Marco Durante</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Charged Particles in Oncology</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (650 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">High-energy charged particles represent a cutting-edge technique in radiation oncology. Protons and carbon ions are used in several centers all over the world for the treatment of different solid tumors. Typical indications are ocular malignancies, tumors of the base of the skull, hepatocellular carcinomas and various sarcomas. The physical characteristics of the charged particles (Bragg peak) allow sparing of much more normal tissues than it is possible using conventional X-rays, and for this reason all pediatric tumors are considered eligible for protontherapy. Ions heavier than protons also display special radiobiological characteristics, which make them effective against radioresistant and hypoxic tumors. On the other hand, protons and ions with high charge (Z) and energy (HZE particles) represent a major risk for human space exploration. The main late effect of radiation exposure is cancer induction, and at the moment the dose limits for astronauts are based on cancer mortality risk. The Mars Science Laboratory (MSL) measured the dose on the route to Mars and on the planet’s surface, suggesting that a human exploration missions will exceed the radiation risk limits. Notwithstanding many studies on carcinogenesis induced by protons and heavy ions, the risk uncertainty remains very high. In this research topic we aim at gathering the experiences and opinions of scientists dealing with high-energy charged particles either for cancer treatment or for space radiation protection. Clinical results with protons and heavy ions, as well as research in medical physics and pre-clinical radiobiology are reported. In addition, ground-based and spaceflight studies on the effects of space radiation are included in this book. Particularly relevant for space studies are the clinical results on normal tissue complications and second cancers. The eBook nicely demonstrates that particle therapy in oncology and protection of astronauts from space radiation share many common topics, and can learn from each other.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">carbon ions</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">heavy ions</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Mars</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">proton therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">radiotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">particle radiobiology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">protons</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">space radiation protection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Charged particles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">space travel</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88945-391-X</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Francis A. Cucinotta</subfield><subfield code="4">auth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jay S. Loeffler</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:57:26 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2019-11-10 04:18:40 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5337595690004498&amp;Force_direct=true</subfield><subfield code="Z">5337595690004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337595690004498</subfield></datafield></record></collection>